Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)
H. A. Ghofrani, F. Grimminger, M. M. Hoeper, N. H. Kim, E. Mayer, G. Simonneau, M. Sikirica, A. Fritsch, N. Davie, B. Luong, M. R. Wilkins (Giessen, Hannover, Bad Nauheim, Berlin, Wuppertal, Germany; San Diego, United States Of America; Le Kremlin-Bicêtre, France; London, United Kingdom)
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Session: Pulmonary circulation: clinical science and treatment
Session type: Poster Discussion
Number: 3418
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. A. Ghofrani, F. Grimminger, M. M. Hoeper, N. H. Kim, E. Mayer, G. Simonneau, M. Sikirica, A. Fritsch, N. Davie, B. Luong, M. R. Wilkins (Giessen, Hannover, Bad Nauheim, Berlin, Wuppertal, Germany; San Diego, United States Of America; Le Kremlin-Bicêtre, France; London, United Kingdom). Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Eur Respir J 2013; 42: Suppl. 57, 3418
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: